The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management, Social Support, Activity Tolerance, and Quality of Life in Patients With Pulmonary Hypertension.

National Defense Medical Center, Taiwan100 enrolled

Overview

Pulmonary arterial hypertension (PAH) is a chronic disease characterized by an elevation in pulmonary artery pressures and pulmonary vascular resistance. The condition most often is rarely detected, and patients frequently suffer symptoms for several years before being appropriately diagnosed. Patients with PH suffer from several symptoms, such as exertional dyspnea, fatigue, weakness, chest pain, fainting…et al. Pulmonary hypertension is an incurable and progressive disease with complex symptoms and treatments. Patients must learn to deal with their unpredictable future and manage the complex treatments associated with severe adverse effects and need significant changes in lifestyle. Therefore, it is important to assist patients to develop the ability of symptom management.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

100

Conditions

Web-based Health Care Program

Interventions

According to the participants' feedback and recommends, we will modify this program to make it more suitable. In the second and third years, we will conduct a parallel-group, double blind, and block randomization, experimental design study to examine the effectiveness of the Pulmonary Hypertension Web-Based Care Program on the improvements of patients' social support, self-care ability, active tolerance, symptom distress, depression, anxiety and quality of life in patients with PAH.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. At least 20 years old, diagnosed by clinical specialists as patients with pulmonary hypertension (Group1 and Group 4) 2. Clear consciousness, able to communicate in Mandarin and Taiwanese, with normal hearing 3. Those who have internet or mobile internet at home 4. Adults without mental illness 5. No alcohol or drug abusers. Exclusion Criteria: 1\. critical disease

Outcomes

Primary Outcomes

Pulmonary Arterial Hypertension Symptom

Pulmonary Arterial Hypertension Symptom Interference Scale, PAHSS, The 10-point Likert scale higher scores mean a worse outcome.

Time frame: Change from Baseline pulmonary Arterial Hypertension Symptom at six months

Secondary Outcomes

Social support

Multidimensional Scale of Perceived Social Support, (MSPSS). The 7-point Likert scale higher scores mean a better outcome.This instrument is 12 questions long and has been widely used and well validated.

Time frame: Change from Baseline social support at six months

Activity ability

6 Minute walk test, 6MWD

Time frame: Change from Baseline activity ability at six months

Pulmonary Hypertension Quality of life

The Cambridge Pulmonary Hypertension Outcome Review, (CAMPHOR). The 5-point Likert scale higher scores mean a better outcome.

Time frame: Change from Baseline quality of life at six months